Drug eruptions

Pharvaris to Present PHA121 Clinical Data for Oral Treatment of Hereditary Angioedema at the EAACI Annual Congress 2021

Retrieved on: 
Thursday, July 1, 2021

ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021.

Key Points: 
  • ZUG, Switzerland, July 01, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that the company will present clinical data for oral PHA121, a novel and potent bradykinin 2 receptor antagonist for treatment of hereditary angioedema, as an e-Poster at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2021, to be held virtually July 10-16, 2021.
  • The virtual poster presentation will be on the EAACI website from July 10-16, 2021, and will be also accessible through the Investors page on the companys website at www.pharvaris.com .
  • Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.
  • These forward-looking statements should not be relied upon as representing Pharvaris views as of any date subsequent to the date of this press release.

Pharvaris Announces Annual Meeting of Shareholders

Retrieved on: 
Friday, June 11, 2021

ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).

Key Points: 
  • ZUG, Switzerland, June 11, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the annual general meeting of shareholders will take place on Tuesday, June 29, 2021 at 1:00 p.m. CEST (7:00 a.m. EDT).
  • All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are or will be made available in the Investors section of Pharvaris website under Events & Presentations.
  • Shareholders who wish to attend the meeting should register as described in the notice and agenda for the annual general meeting.
  • Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.

Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE, at 12th C1 Inhibitor Deficiency and Angioedema Workshop

Retrieved on: 
Friday, June 4, 2021

Pharvaris is proud to be a sponsor for the 12th C1 Inhibitor Deficiency and Angioedema Workshop, said Dr. Lesage.

Key Points: 
  • Pharvaris is proud to be a sponsor for the 12th C1 Inhibitor Deficiency and Angioedema Workshop, said Dr. Lesage.
  • These data position PHA121 as a potentially valuable treatment option for both on-demand and prophylactic treatment of HAE.
  • The model was validated utilizing icatibant, a marketed injectable B2 receptor antagonist, providing back-translation from human clinical experience with icatibant.
  • The objective of the study was to investigate the ability of PHA121 to attenuate blood-pressure changes induced by bradykinin injection.

Pharvaris to Participate in BioCapital Europe

Retrieved on: 
Thursday, March 4, 2021

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.

Key Points: 
  • ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that Berndt Modig, chief executive officer and co-founder of Pharvaris, will participate in BioCapital Europe, to be held virtually on March 11, 2021.
  • Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients.
  • By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases.
  • The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE.

Pharvaris Announces Closing of Initial Public Offering

Retrieved on: 
Tuesday, February 9, 2021

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (Pharvaris) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the closing of its initial public offering of 9,511,075 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $190.2 million.

Key Points: 
  • ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (Pharvaris) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the closing of its initial public offering of 9,511,075 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $190.2 million.
  • The number of ordinary shares issued at closing included the exercise in full of the underwriters option to purchase 1,240,575 additional ordinary shares.
  • Morgan Stanley, BofA Securities, and SVB Leerink acted as joint book-running managers of the offering, and Oppenheimer & Co. and Kempen & Co acted as co-managers.
  • A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on February 4, 2021.

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

Retrieved on: 
Monday, June 8, 2020

HATTERSHEIM, Germany, June 8, 2020 /PRNewswire/ -- CSL Behring , a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an investigational novel Factor XIIa-inhibitory monoclonal antibody (FXIIa mAb) in development as a preventive treatment in hereditary angioedema (HAE).

Key Points: 
  • HATTERSHEIM, Germany, June 8, 2020 /PRNewswire/ -- CSL Behring , a global biotherapeutics leader, today announced results of a Phase 2 clinical trial for garadacimab (previously known as CSL312), an investigational novel Factor XIIa-inhibitory monoclonal antibody (FXIIa mAb) in development as a preventive treatment in hereditary angioedema (HAE).
  • Additionally, last month, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to garadacimab as an investigational therapy for the prevention of bradykinin-mediated angioedema, which includes both hereditary and non-hereditary (acquired) angioedema.
  • CSL Behring is also investigating garadacimab for other indications, beyond HAE, where FXIIa inhibition may be a factor in improving clinical outcomes.
  • CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

CSL Behring Presents Results for Garadacimab as Preventive Treatment in Hereditary Angioedema

Retrieved on: 
Monday, June 8, 2020

Additionally, last month, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to garadacimab as an investigational therapy for the prevention of bradykinin-mediated angioedema, which includes both hereditary and non-hereditary (acquired) angioedema.

Key Points: 
  • Additionally, last month, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to garadacimab as an investigational therapy for the prevention of bradykinin-mediated angioedema, which includes both hereditary and non-hereditary (acquired) angioedema.
  • CSL Behring is also investigating garadacimab for other indications, beyond HAE, where FXIIa inhibition may be a factor in improving clinical outcomes.
  • The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.
  • CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

Wormington and Bollinger files Lawsuit alleging SJS and TEN are caused by a drug distributed by Prometheus Laboratories, Inc

Retrieved on: 
Tuesday, November 19, 2019

This prescription medication is made and marketed by the San Diego-based pharmaceutical company, Prometheus.

Key Points: 
  • This prescription medication is made and marketed by the San Diego-based pharmaceutical company, Prometheus.
  • Plaintiff alleges in the lawsuit that Prometheus failed to fully warn consumers and physicians of the harmful side effects of Zyloprim, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Plaintiff's Complaint alleges that SJS and TEN are extremely serious conditions that are often times fatal or result in catastrophic permanent injuries.
  • Allopurinol is a known cause of SJS and TEN, yet Prometheus failed to warn consumers of important information concerning this potential side effect.

Kyowa Kirin Presents Post-Hoc Analysis of Pivotal Trial for Poteligeo® (mogamulizumab-kpkc)

Retrieved on: 
Monday, June 3, 2019

Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).

Key Points: 
  • Permanently discontinue POTELIGEO for life-threatening (Grade 4) rash or for any Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN).
  • Complications of allogeneic HSCT after POTELIGEO: Increased risks of transplant complications have been reported in patients who received allogeneic HSCT after POTELIGEO.
  • You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
  • Kyowa Hakko Kirin Co., Ltd. is a research-based life sciences company, with special strengths in biotechnologies.

Omixon & PIRCHE® collaborate on Epitope Determination with NGS

Retrieved on: 
Thursday, September 20, 2018

PIRCHE has implemented the first HLA epitope matching algorithm that takes into account the indirect pathway of allo-recognition by identifying possible T cell epitopes introduced by mismatched HLA.

Key Points: 
  • PIRCHE has implemented the first HLA epitope matching algorithm that takes into account the indirect pathway of allo-recognition by identifying possible T cell epitopes introduced by mismatched HLA.
  • Omixon will integrate the PIRCHE epitope prediction and matching service from within HLA Twin - the world's leading NGS analysis software for HLA that uses two algorithms to reliably determine whole gene consensus sequences from targeted HLA data generated from Holotype HLA.
  • "Omixon is delighted to enter a partnership with PIRCHE to enable our users with groundbreaking epitope prediction and matching algorithms.
  • I am delighted to see this collaboration between PIRCHE and Omixon going forward" says Attila Berces, Founder and Chairman at Omixon.